Establishing the epigenetic status of the Prader-Willi/Angelman imprinting center in the gametes and embryo

Department of Cellular Biochemistry and Human Genetics, The Hebrew University, Hadassah Medical School, Jerusalem, Israel.
Human Molecular Genetics (Impact Factor: 6.68). 12/2004; 13(22):2767-79. DOI: 10.1093/hmg/ddh290
Source: PubMed

ABSTRACT The Prader-Willi/Angelman imprinted domain on human chromosome 15q11-q13 is regulated by an imprinting control center (IC) composed of a sequence around the SNRPN promoter (PWS-SRO) and a sequence located 35 kb upstream (AS-SRO). We have previously hypothesized that the primary imprint is established on AS-SRO, which then confers imprinting on PWS-SRO. Here we examine this hypothesis using a transgene that includes both AS-SRO and PWS-SRO sequences and carries out the entire imprinting process. The epigenetic features of this transgene resemble those previously observed on the endogenous locus, thus allowing analyses in the gametes and early embryo. We demonstrate that the primary imprint is in fact established in the gametes, creating a differentially methylated CpG cluster (DMR) on AS-SRO, presumably by an adjacent de novo signal (DNS). The DMR and DNS bind specific proteins: an allele-discrimination protein (ADP) and a de novo methylation protein, respectively. ADP, being a maternal protein, is involved in both the establishment of DMR in the gametes and in its maintenance through implantation when methylation of PWS-SRO on the maternal allele takes place. Importantly, while the AS-SRO is required in the gametes to confer methylation on PWS-SRO, it is dispensable later in development.

Download full-text


Available from: Aharon Razin, Jun 18, 2015
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Despite the major advancements during the last decade with respect to both knowledge of higher order chromatin organization in the cell nucleus and the elucidation of epigenetic mechanisms of gene control, the true three-dimensional (3D) chromatin structure of endogenous active and inactive gene loci is not known. The present study was initiated as an attempt to close this gap. As a model case, we compared the chromatin architecture between the genetically active and inactive domains of the imprinted Prader-Willi syndrome (PWS) locus in human fibroblast and lymphoblastoid cell nuclei by 3D fluorescence in situ hybridization and quantitative confocal laser scanning microscopy. The volumes and 3D compactions of identified maternal and paternal PWS domains were determined in stacks of light optical serial sections using a novel threshold-independent approach. Our failure to detect volume and compaction differences indicates that possible differences are below the limits of light optical resolution. To overcome this limitation, spectral precision distance microscopy, a method of localization microscopy at the nanometer scale, was used to measure 3D distances between differentially labeled probes located both within the PWS region and in its neighborhood. This approach allows the detection of intranuclear differences between 3D distances down to about 70-90 nm, but again did not reveal clearly detectable differences between active and inactive PWS domains. Despite this failure, a comparison of the experimental 3D distance measurements with computer simulations of chromatin folding strongly supports a non-random higher order chromatin configuration of the PWS locus and argues against 3D configurations based on giant chromatin loops. Our results indicate that the search for differences between endogenous active and inactive PWS domains must be continued at still smaller scales than hitherto possible with conventional light microscopic procedures. The possibilities to achieve this goal are discussed.
    Differentiation 02/2008; 76(1):66-82. DOI:10.1111/j.1432-0436.2007.00237.x · 2.84 Impact Factor
  • Source
    Dataset: Diss Wagner
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: One of the epigenetic mechanisms by which gene expression is regulated is the methylation of DNA. Erroneous DNA methylation can cause a vast spectrum of diseases. A mouse model was created in this study to investigate whether the overexpression of the somatic form of Dnmt1, Dnmt1s, is sufficient to cause erroneous methylation and disease. A CAG promoter-driven transgene containing the Dnmt1s DNA methyltransferase was constructed. Transgene functionality was tested in 3T3 murine fibroblasts in cell culture. Because the ubiquitous overexpression of Dnmt1 has been reported to be embryonically lethal, a conditional transgene was constructed using the Cre-LoxP system. This technique allows the initial expression of the eGFP marker protein only. Upon cross-ins with Cre-recombinant mouse lines, the eGFP sequence is cut out and degraded. This leads to the expression of the Dnmt1s under control of the CAG promoter. To easily distinguish between endogenous and transgenic methyltransferase, a RGS-His-tag was added to the N-terminal end of the Dnmt1s transgene. Pronucleus injections with the Dnmt1s transgene resulted in six founder lines verified by PCR, Southern blot and eGFP fluorescence. Cross-ins of these founders with CMV-Cre mouse lines yielded viable offspring. The ubiquitous overexpression of Dnmt1s was investigated in cross-ins that carry the recombined version of the Dnmt1s transgene and express RGS-His-tagged Dnmt1 as verified by RT-PCR. TaqMan analyses of total Dnmt1 expression of the line with the strongest overexpression showed a ~ 3-fold (3.17 ± 0.65) overexpression in liver, a ~ 3.5-fold (3.47 ± 0.15) overexpression in testis, a ~ 5.5-fold (5.44 ± 0.39) overexpression in brain and a ~ 6-fold (6.24 ± 1.48) overexpression in kidney, but no overexpression in the spleen of CMV-Cre recombined transgenic mice in comparison to sibling wild type controls. Dnmt1 overexpression was confirmed on the protein level by quantitative western blots, which detected ~ 3-fold Dnmt1 levels in brain and ~ 6-fold Dnmt1 levels in testis of transgenic mice in comparison to sibling wild type controls. Upcoming analyses will test the in vivo functionality of the transgenic protein and the phenotypic consequences of Dnmt1s overexpression.